Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated at initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCAFree Report) in a research report sent to investors on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Genocea Biosciences Stock Performance

Genocea Biosciences has a 1 year low of $0.00 and a 1 year high of $0.00. The stock has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.

About Genocea Biosciences

(Get Free Report)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Further Reading

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with's FREE daily email newsletter.